Meitheal's Garzulys gains FDA approval as new competitor in rapidly expanding insulin biosimilar market

Meitheal Pharmaceuticals has received FDA approval for Garzulys, a biosimilar of Novo Nordisk’s NovoLog, marking a significant step in the increasing competition in rapid-acting insulin options in the US market. Meitheal Pharmaceuticals has won United States approval for Garzulys, a…





